ALIZES PHARMA is younger than twelve months; there is no public track record yet to compute a bankruptcy probability from. The company has been active since 2026 and the Belgian State Gazette contains no insolvency or warning signals. No processed annual-account figures are available; this conclusion rests on registry and State Gazette data only.
Signals
Two signals. The signal on the left, the evidence on the right.
+raises risk○neutral
raises risk · Young company
Founded in 2026, under 3 years, statistically higher risk.
KBO · incorporation dateAge against the risk zone
Financials
No annual accounts filed
No annual accounts of this company are filed with the National Bank. As a Private limited company it is required to file; a dormant company does still have to file.
Timeline · acts, filings and financial milestones
2026
20-07
State Gazette act
IncorporationIncorporation · Founder · Founding capital17 facts ▸
State Gazette act
Incorporation
Incorporation · Founder · Founding capital17 facts ▸
- Incorporation, 16 juillet 2026
- Founder, AQUILON PHARMACEUTICALS
- Founding capital, €15.000
- Corporate purpose, la recherche, le développement, la formulation, la caractérisation, la mise au point, la production et la valorisation de solutions thérapeutiques destinées à l…
- First fiscal year, 31 décembre 2027, 16 juillet 2026
- Director appointment, MAES PHARMCONSULT (administrateur)
- Permanent representative, MAES Paul
- Director appointment, MILEGRAND (administrateur)
- Permanent representative, LEGRAND Michaël Philippe Michel
- Director appointment, CATALDO Didier Daniel Claude Philippe (administrateur)
- Director appointment, NELLES Charles Henri Alex (administrateur)
- Director appointment, MAES PHARMCONSULT (Président du Collège d’administrateurs)
- +5 further facts in this act
State Gazette act
Directors · office · real estate
Directors
under verification, no change since 2026
This board is reconstructed from a single act (26347107). A Gazette act generally publishes only CHANGES, not a full roll call, so directors unchanged since then may be missing here. The KBO register holds the complete list of function holders.
CATALDO Didier Daniel Claude Philippe
CurrentDirector · since 20-07-2026
MAES PHARMCONSULT
CurrentDirector · since 20-07-2026 · Legal entity
MILEGRAND
CurrentDirector · since 20-07-2026 · Legal entity
NELLES Charles Henri Alex
CurrentDirector · since 20-07-2026
20-07-2026
CATALDO Didier Daniel Claude Philippe: Director of as Director
20-07-2026
MAES PHARMCONSULT: Director of as Director
20-07-2026
MAES PHARMCONSULT: Director of as Président du collège d’administrateurs
20-07-2026
MILEGRAND: Director of as Director
20-07-2026
MILEGRAND: Director of as Managing director
20-07-2026
NELLES Charles Henri Alex: Director of as Director
Location & real-estate footprint
Registered office, Seraing
Cannot be placed on the map
This address could not be matched to a point in the Belgian address register (BOSA BEST). The address below comes straight from the Crossroads Bank.
Rue du Bois St-Jean 15/14102 SeraingStructure & network
Capital and shareholders
Founding capital 15,000 EUR · 1,000 shares
founder: AQUILON PHARMACEUTICALS (BE 0540.870.218)
Company data · Crossroads Bank
Identification
Legal formPrivate limited company
Founded16-07-2026
Sources
Crossroads Bank for Enterprises
Data from official sources, last processed on 13-09-2026. Scores and ratios are computed by Checked and are not a credit decision.